

Meeting with European Federation of Pharmaceutical Industries and Associations (EFPIA) 22 April 2015

Participants:

EFPIA:

David Ricks, Board member of EFPIA for Eli Lilly, chair of EFPIA International Market Committee

Art. 4.1 b, Eli Lilly
Art. 4.1 b, EFPIA

Commission:

Jean-Luc Demarty, Director General TRADE

Art. 4.1 b, TRADE G3
Art. 4.1 b, TRADE B3

Summary:

The meeting focused on TTIP out of scope.

As regards TTIP, EFPIA expressed its conviction that TTIP could contribute to economic growth on both sides of the Atlantic, and underlined that the pharmaceutical industry is a driver for growth and jobs, a major employer and high investor in R&D. EFPIA explained the importance of the pharmaceutical sector, in which the EU and US have together a share of 80% of the global production, with more than half of the manufacturing located in the EU.

EFPIA reminded of its objectives and concerns on TTIP, which are well known from the EU and US industry joint submission and EFPIA's position papers. EFPIA mentioned specifically the regulatory convergence (mutual recognition of GMP inspections, alignment of scientific advice, and a more structured mechanism to synchronize new regulation), IPR (putting in the agreement the shared high standards on IPR), and state procurement/market access for pharmaceuticals in the EU. EFPIA referred to problems with the present lack of a common enforcement mechanism of the European patent and the different market access schemes for pharmaceuticals in the various EU Member States.

[out of scope]

[out of scope]

[out of scope]

[out of scope]